3D IMAGING DRUG DESIGN & DEVELOPMENT LLC
3D IMAGING DRUG DESIGN & DEVELOPMENT LLC is a federal contractor, registered under UEI W1SFM4QYMTV5 and CAGE code 4V2L0. It has been awarded $4,102,148 across 10 federal contracts. Primary work spans Research and Development in Biotechnology, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology), and Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). Top awarding agencies include Department Of Health And Human Services.
Contact Information
Registration and classification details
Registration
UEI Code
W1SFM4QYMTV5CAGE Code
4V2L0Entity Structure
Partnership or Limited Liability PartnershipEstablished
N/ABusiness Classifications
NAICS Codes
Federal Contracting Overview
Award totals, agency breakdown, NAICS distribution, and geographic footprint.
AI Capability Profile
3D IMAGING DRUG DESIGN & DEVELOPMENT LLC specializes in the design, synthesis, and delivery of radiotracers for biomedical research and diagnostic applications, leveraging advanced 3D imaging techniques to support drug development workflows. The company’s core expertise lies in radiochemistry, molec...
3D IMAGING DRUG DESIGN & DEVELOPMENT LLC specializes in the design, synthesis, and delivery of radiotracers for biomedical research and diagnostic applications, leveraging advanced 3D imaging techniques to support drug development workflows. The company’s core expertise lies in radiochemistry, molecular imaging, and the engineering of targeted radiolabeled compounds for use in preclinical and clinical settings. Their work integrates physical chemistry, nuclear medicine, and computational modeling to optimize tracer kinetics, biodistribution, and signal-to-noise ratios—critical factors in PET and SPECT imaging. Key differentiators include precision synthesis methodologies and end-to-end delivery systems that bridge laboratory innovation with operational feasibility in regulated environments. The contractor has delivered services to the Department of Health and Human Services, specifically supporting initiatives under 18F focused on digital health infrastructure. Their engagement centers on developing and deploying radiotracer technologies that enhance diagnostic accuracy and accelerate therapeutic evaluation, aligning with HHS priorities in precision medicine and imaging innovation. The primary NAICS code, 541715, reflects a focus on research and development in the life sciences, excluding nanotechnology and biotechnology. This positions the firm squarely within the radiopharmaceutical and molecular imaging sector, serving the growing demand for non-invasive diagnostic tools in oncology, neurology, and cardiology. Their market niche is defined by technical rigor in tracer development and a systems-level approach to imaging agent delivery. As a small business structured under the 2K designation, the company operates from Little Rock, Arkansas, with no federal certifications on record. While limited in public certification status, its specialized technical output demonstrates a focused capability in a high-barrier, high-impact segment of the federal life sciences market.
Key Performance Metrics
Awards Count
All time
Active
Currently performing
Completed
Past period of performance
Total Awards
All time
Contracts
Prime · all time
Subcontracts
Sub · all time
Grants
Prime · all time
Subgrants
Sub · all time
